KNSA Kiniksa Pharmaceuticals Ltd.

5.88
-0.07  -1%
Previous Close 5.95
Open 5.99
Price To Book 1.17
Market Cap 322,563,229
Shares 54,857,692
Volume 155,799
Short Ratio
Av. Daily Volume 87,844
Stock charts supplied by TradingView

NewsSee all news

  1. Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

    HAMILTON, Bermuda, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2020.
Rilonacept (RHAPSODY)
Pericarditis
Phase 2 data due 2H 2020.
Mavrilimumab
Giant cell arteritis (GCA)
Phase 1b data showed no meaningful benefit - August 12, 2019.
KPL-716
Atopic dermatitis
Phase 2 data due 1H 2020.
KPL-716
Prurigo nodularis
Phase 2 open-label data to be presented at AHA November 16, 2019, 4:30 p.m.
Rilonacept
Pericarditis
Phase 2 data due throughout 2020.
KPL-716
Chronic Pruritus

Latest News

  1. Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

    HAMILTON, Bermuda, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic